Re: Glivec,Tasigna,Sprycel wirken nicht! Ponatinib Erfahrung
Verfasst: 19.09.2013, 08:56
Hallo Felice,
meines (Laien)wissens gibt es wohl auch noch die Option, Dir Spenderlymphozyten zu geben, so genannte DLI (Donor lymphocyte infusion). Diese sollen insbesondere bei der CML sehr effektiv sein.
Anbei ein Abstract von 1999, aus dem hervor geht, das DLI eine bewährte Therapie bei CML ist.
Haben Deine Ärzte diese Option erwähnt?
http://www.cmleukemia.com/donor-lymphoc ... n-dli.html
Donor lymphocyte infusions
The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusions [DLI]) is remarkably effective in treating chronic myeloid leukemia in relapse after allogeneic stem cell transplantation. DLI are less effective in acute leukemia and other hematologic tumors, but the use of interleukin-2 in conjunction with DLI after allograft may increase the response rate. The use of DLI to treat certain solid tumors is under investigation. In contrast, the value of donor lymphocytes for treating infectious complications post-transplant and graft failure has been established. The major drawback of DLI remains graft-versus-host disease, but novel regimens of administration and/or selective manipulation of donor cells prior to infusion have reduced its incidence. Further progresses in this area will help to establish the role of nonmyeloablative conditioning for allografting.
Extract of http://journals.lww.com/co-hematology/A ... ons.7.aspx
Dir alles Gute!
Frieda
meines (Laien)wissens gibt es wohl auch noch die Option, Dir Spenderlymphozyten zu geben, so genannte DLI (Donor lymphocyte infusion). Diese sollen insbesondere bei der CML sehr effektiv sein.
Anbei ein Abstract von 1999, aus dem hervor geht, das DLI eine bewährte Therapie bei CML ist.
Haben Deine Ärzte diese Option erwähnt?
http://www.cmleukemia.com/donor-lymphoc ... n-dli.html
Donor lymphocyte infusions
The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusions [DLI]) is remarkably effective in treating chronic myeloid leukemia in relapse after allogeneic stem cell transplantation. DLI are less effective in acute leukemia and other hematologic tumors, but the use of interleukin-2 in conjunction with DLI after allograft may increase the response rate. The use of DLI to treat certain solid tumors is under investigation. In contrast, the value of donor lymphocytes for treating infectious complications post-transplant and graft failure has been established. The major drawback of DLI remains graft-versus-host disease, but novel regimens of administration and/or selective manipulation of donor cells prior to infusion have reduced its incidence. Further progresses in this area will help to establish the role of nonmyeloablative conditioning for allografting.
Extract of http://journals.lww.com/co-hematology/A ... ons.7.aspx
Dir alles Gute!
Frieda